Skip Navigation LinksHome > December 2007 - Volume 13 - Issue 12 > IBD serological panels: Facts and perspectives
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20226
Clinical Review: IBD Serological Panels

IBD serological panels: Facts and perspectives

Peyrin‐Biroulet, Laurent MD1; Standaert‐Vitse, Annie PhD2; Branche, Julien MD1; Chamaillard, Mathias PhD1

Collapse Box

Abstract

Abstract: Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology.

(Inflamm Bowel Dis 2007)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.